UBT251

Status

In trials. Investigational. Developed by United Biotechnology and licensed exclusively to Novo Nordisk in March 2025. Phase 3 trials in obesity and type 2 diabetes were registered in 2026; it is not FDA-approved, and no approval elsewhere is listed in this entry's sources.

What it is

A triple agonist — one peptide engaging the GLP-1, GIP and glucagon receptors, the same three-receptor design as retatrutide, arriving from a different developer through Novo Nordisk's licensing deal.

What published research measured

A Chinese phase 2 trial in overweight or obesity reported mean weight loss of up to 19.7% after 24 weeks (company announcement, February 2026). A second phase 2 in type 2 diabetes reported HbA1c reductions of up to 2.16% (March 2026). Both were topline announcements, not peer-reviewed publications, and the trials were conducted in China. Cross-trial comparisons with retatrutide and the other triple agonists are unreliable.

Source

Novo Nordisk / The United Laboratories announcements, Feb–Mar 2026; ClinicalTrials.gov NCT07648225, NCT07653477

Sources

• Primary source
• CDC handling principles
• ClinicalTrials.gov NCT07648225
• ClinicalTrials.gov NCT07653477